Breaking Finance News

ProMetic Life Sciences (TSE:PLI) target price lowered to $4.00, issued a report today by Scotia Capital

ProMetic Life Sciences (TSE:PLI) had its target price lowered to $4.00 by Scotia Capital in a report released 07/07/2017. The new target price indicates a possible upside of 1.53% based on the company's last stock close price.

Previously on Monday June 19, 2017, Canaccord Genuity reported about ProMetic Life Sciences (TSE:PLI) lowered the target price from $4.75 to $4.50. At the time, this indicated a possible upside of 1.56%.

Boasting a price of $1.58, ProMetic Life Sciences (TSE:PLI) traded -5.44% lower on the day. With the last close down -31.25% from the two hundred day average, compared with the S&P 500 Index which has increased 0.05% over the date range. ProMetic Life Sciences has recorded a 50-day average of $1.61 and a two hundred day average of $2.02. Volume of trade was up over the average, with 1,109,398 shares of PLI changing hands over the typical 631,127

Performance Chart

ProMetic Life Sciences (TSE:PLI)

With a total market value of $0, ProMetic Life Sciences has with a one year low of $1.21 and a one year high of $3.24 .

A total of 10 analysts have released a research note on PLI. Two analysts rating the company a strong buy, eight analysts rating the company a buy, one analyst rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $3.96.

More About ProMetic Life Sciences (TSE:PLI)

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs. ProMetic is also developing its own small molecule therapeutic products targeting unmet medical needs in the field of fibrosis, autoimmune disease/inflammation and cancer. It has research and development facilities in the United Kingdom, the United States and Canada; manufacturing facilities in the Isle of Man and Canada, and business development activities in the United States, Europe and Asia.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.